


## WHAT IS CLAIMED IS:

1                    1.        A composition for the treatment of proliferative disorders,  
2 comprising an antineoplastic agent and a compound having the formula:



3  
4 and pharmaceutically acceptable salts thereof;  
5 wherein

6                    R is a member selected from the group consisting of hydrogen and  
7 substituted or unsubstituted (C<sub>1</sub>-C<sub>10</sub>)alkyl; and

8                    Ar is a member selected from the group consisting of substituted or  
9 unsubstituted aryl and substituted or unsubstituted heteroaryl

1                    2.        A composition in accordance with claim 1, wherein said  
2 antineoplastic agent is selected from the group consisting of DNA-alkylating agents,  
3 antimetabolites, antifolates and other inhibitors of DNA synthesis, microtubule disruptors,  
4 DNA intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents,  
5 growth factor receptor kinase inhibitors, biological response modifiers, antiangiogenic  
6 and antivascular agents, immunoconjugates and antisense oligonucleotides.

1                    3.        A composition in accordance with claim 1, wherein said  
2 antineoplastic agent is selected from the group consisting of cyclophosphamide, BCNU,  
3 busulfan, temozolomide, UFT, capecitabine, gemcitabine, cytarabine, improsulfan,  
4 piposulfan, benzodepa, carboquone, meturedpa, uredepa, altretamine,  
5 triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate,  
6 trimethylolmelamine, chlorambucil, estramustine, ifosfamide, novembrichin,  
7 prednimustine, uracil mustard, dacarbazine, fluorouracil, methotrexate, mercaptopurine,  
8 thioguanine, vinblastine, vincristine, vinorelbine, vindesine, etoposide, teniposide,  
9 daunorubicin, doxorubicin, epirubicin, mitomycin, dactinomycin, daunomycin,  
10 plicamycin, bleomycin, L-asparaginase, camptothecin, hydroxyurea, procarbazine,  
11 mitotane, aminoglutethimide, tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol,  
12 and thiotepa.

13                   4.       A composition in accordance with claim 1, wherein said  
14 antineoplastic agent is selected from the group consisting of doxorubicin, daunorubicin,  
15 gemcitabine and paclitaxel.






16                   5.       A composition in accordance with claim 1, wherein said  
17 antineoplastic agent is gemcitabine or paclitaxel.

1                   6.       A composition in accordance with claim 1, wherein R is hydrogen  
2 or unsubstituted (C<sub>1</sub>-C<sub>4</sub>)alkyl.

1                   7.       A composition in accordance with claim 1, wherein Ar is a  
2 substituted phenyl group.



1                   8.       A composition in accordance with claim 7, wherein said  
2 substituents on said phenyl group are selected from the group consisting of halogen, (C<sub>1</sub>-  
3 C<sub>4</sub>)alkoxy, (C<sub>1</sub>-C<sub>4</sub>)alkyl, -OPO<sub>3</sub>H<sub>2</sub>,

1                   9.       A composition in accordance with claim 8, wherein Ar represents a  
2 member selected from the group consisting of



3


- 1                    10.    A composition in accordance with claim 1, wherein said compound  
2    is selected from the group consisting of:



3

1 11. A method for the treatment of a proliferative disorder, comprising  
2 administering to a subject in need of such treatment an effective amount of a composition  
3 of claim 1.

1 12. A. method in accordance with claim 11, wherein said compound is  
2 selected from the group consisting of:



6 13. A method in accordance with claim 12, wherein said antineoplastic  
7 agent is selected from the group consisting of DNA-alkylating agents, antimetabolites,  
8 antifolates and other inhibitors of DNA synthesis, microtubule disruptors, DNA  
9 intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents, growth  
10 factor receptor kinase inhibitors, biological response modifiers, antiangiogenic and  
11 antivascular agents, immunoconjugates and antisense oligonucleotides.

1 14. A method in accordance with claim 12, wherein said antineoplastic  
2 agent is selected from the group consisting of cyclophosphamide, BCNU, busulfan,  
3 temozolomide, UFT, capecitabine, gemcitabine, cytarabine, improsulfan, pipsulfan,  
4 benzodepa, carboquone, meturedpa, uredepa, altretamine, triethylenemelamine,  
5 triethylenephosphoramidate, triethylenethiophosphoramidate, trimethylolmelamine,  
6 chlorambucil, estramustine, ifosfamide, novembrichin, prednimustine, uracil mustard,  
7 dacarbazine, fluorouracil, methotrexate, mercaptopurine, thioguanine, vinblastine,

vincristine, vinorelbine, vindesine, etoposide, teniposide, daunorubicin, doxorubicin, epirubicin, mitomycin, dactinomycin, daunomycin, plicamycin, bleomycin, L-asparaginase, camptothecin, hydroxyurea, procarbazine, mitotane, aminoglutethimide, tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol, and thiotepa.


**15.** A method in accordance with claim 12, wherein said antineoplastic agent is selected from the group consisting of doxorubicin, daunorubicin, gemcitabine and paclitaxel.

**16.** A method in accordance with claim 12, wherein said antineoplastic agent is gemcitabine or paclitaxel.

**17.** A method for the treatment of a proliferative disorder, comprising administering to a subject in need of such treatment:

i) a first amount of an antineoplastic agent; and

ii) a second amount of a compound of formula:





and pharmaceutically acceptable salts thereof; wherein

R is a member selected from the group consisting of hydrogen and substituted or unsubstituted (C<sub>1</sub>-C<sub>10</sub>)alkyl; and


Ar is a member selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl;

wherein said first amount and said second amount, in combination, are effective to treat said proliferative disorder

**18.** A method in accordance with claim 17, wherein said compound is selected from the group consisting of



and



19. A method in accordance with claim 18, wherein said antineoplastic agent is selected from the group consisting of DNA-alkylating agents, antimetabolites, antifolates and other inhibitors of DNA synthesis, microtubule disruptors, DNA intercalators, hormone agents, topoisomerase I/II inhibitors, DNA repair agents, growth factor receptor kinase inhibitors, biological response modifiers, antiangiogenic and antivasular agents, immunoconjugates and antisense oligonucleotides.

20. A method in accordance with claim 18, wherein said antineoplastic agent is selected from the group consisting of cyclophosphamide, BCNU, busulfan, temozolomide, UFT, capecitabine, gemcitabine, cytarabine, improsulfan, piposulfan, benzodepa, carboquone, meturedpa, uredepa, altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate, trimethylolmelamine, chlorambucil, estramustine, ifosfamide, novembrichin, prednimustine, uracil mustard, dacarbazine, fluorouracil, methotrexate, mercaptopurine, thioguanine, vinblastine, vincristine, vinorelbine, vindesine, etoposide, teniposide, daunorubicin, doxorubicin, epirubicin, mitomycin, dactinomycin, daunomycin, plicamycin, bleomycin, L-asparaginase, camptothecin, hydroxyurea, procarbazine, mitotane, aminoglutethimide, tamoxifen, flutamide, mitoxantrone, paclitaxel, docetaxol, and thiotepa.

21. A method in accordance with claim 18, wherein said antineoplastic agent is selected from the group consisting of doxorubicin, daunorubicin, gemcitabine and paclitaxel.

15                   **22.**     A method in accordance with claim 18, wherein said antineoplastic  
16 agent is gemcitabine or paclitaxel.

17  
18                   **23.**     A method in accordance with claim 18, wherein said antineoplastic  
19 agent is administered prior to said compound.

20  
21                   **24.**     A method in accordance with claim 18, wherein said antineoplastic  
22 agent is administered after said compound.

23  
24                   **25.**     A method in accordance with claim 18, wherein said antineoplastic  
25 agent is administered simultaneously with said compound.